Latest "Galectin Therapeutics" News Stories

03:54 EDT 3rd July 2015 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 46

Relevant

Galectin Therapeutics: Where There Is Smoke There Is Fire

Galectin Therapeutics to Present at LD Micro Invitational Conference

NORCROSS, Ga., May 28, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that James Czirr, executive chairman, will present a corporate overview and update at the LD Micro Invitational Conference on June 2, 2015, at 4:00 p.m. Pacific time. The conference is being held at t...

Galectin Therapeutics Announces Details of the Design of Its Phase 2 Program With GR-MD-02

Program to include one trial to confirm the safety and therapeutic effect on fibrosis in NASH patients with cirrhosis, and a smaller trial to confirm the safety and therapeutic effect on NASH patients with advanced fibrosis Both studies to begin in the second quarter of 2015 Company to submit a Special Protocol Assessment to the FDA by the end of the month NORCROSS, Ga., Feb. 24...

Galectin Therapeutics to Present at the 27th Annual ROTH Conference

NORCROSS, Ga., March 2, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that Harold, Shlevin, Ph.D, chief operating officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 9, 2015 at 11:00 a.m. Pacific time. The conference is bei...

BG Medicine Submits 510(k) to FDA for Additional Indication for the BGM Galectin-3(R) Test

WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported that it has filed a 510(k) Premarket Notification with U.S. Food and Drug Administration (FDA) for regulatory clearance of an additional indication for the BGM Galectin-3 Test. The filing incorporates data generated from a study in which levels of the pr...

Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update

NORCROSS, Ga., March 18, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the year ended December 31, 2014. These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commiss...

Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders

NORCROSS, Ga., May 15, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will webcast a corporate update at 9:45 A.M. ET on Thursday, May 21, 2015, immediately following the business portion of the Company's Annual Meeting of Stockholders. Additionally, Peter Traber, M.D., president, chief executive officer and chief medical officer will discuss the Company's pipeline of galectin inhib...

Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director

NORCROSS, Ga., June 3, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that Marc Rubin, M.D. has been elected by the independent members of the board of directors as the lead independent director. Dr. Rubin has been a member of the Galectin board of directors since 2011 and...

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential

Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

NORCROSS, Ga., June 29, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis. This study, the NASH-CX trial, is a multicenter, randomi...

Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

NORCROSS, Ga., March 24, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces that Peter G. Traber, M.D., president, chief executive officer and chief medical officer, delivered an invited presentation of the Company's research with lead compound GR-MD-02 in non-alcoholic steatohep...

Galectin Therapeutics Engages PPD to Conduct GR-MD-02 Phase 2 Trial in NASH, Submits Special Protocol Assessment to FDA

NORCROSS, Ga., March 12, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces it has engaged the contract research organization Pharmaceutical Product Development, LLC (PPD) to conduct the Phase 2 trial with GR-MD-02 for the treatment of liver fibrosis and resultant portal hyperten...

The Galectin-9/Tim-3 pathway is involved in the regulation of NK cell function at the maternal–fetal interface in early pregnancy

Galectin Therapeutics Reports First Quarter 2015 Financial Results, Provides Business Update Including Phase 2 NASH Program

NORCROSS, Ga., May 11, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three months ended March 31, 2015. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange C...

Targeted inhibition of galectin 1 by thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats

Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

NORCROSS, Ga., May 14, 2015 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that in an open-label Phase 1 study with 8 mg/kg dose of GR-MD-02 and 2 mg/kg dose of midazolam there was no drug-drug interaction and no serious adverse events or drug-related adverse events were observ...

Image of the Day: Snail Blood

The galectin proteins (green) expressed in snail hemocytes—which are equivalent to human white blood cells—bind to the parasitic worm that causes schistosomiasis in people.

La Jolla begins Phase IIb trial of GCS-100 to treat advanced CKD

US-based biotechnology firm La Jolla Pharmaceutical has started a Phase IIb clinical trial of its galectin-3 inhibitor, GCS-100, to treat advanced chronic kidney disease (CKD) caused by diabetes.

Probably Relevant

La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview a...

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that it has initiated its Phase 2b clinical trial of GCS-100 for the treatment of advanced

Patent Awarded for New Anti-Cancer Botanical Combination

SANTA ROSA, Calif., Feb. 3, 2015 /PRNewswire/ -- Dr. Isaac Eliaz, a widely respected integrative medical doctor and researcher, has been awarded a USA patent from the U.S. Patent and Trademark Office for his innovative combination of modified citrus pectin (MCP) and honokiol extract from magnolia tree bark. This combination has broad, multi-targeted potential to help stop the growth and sprea...

Modified Citrus Pectin Enhances Radiation Therapy in Prostate Cancer Treatment

PHILADELPHIA, April 22, 2015 /PRNewswire/ -- Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. Results were presented today at the American Association for Cancer Research (AACR) Annual Me...

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that Dennis Mulroy will join the Company as Chief Financial Officer, effective today. “Dennis brings ...

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported fourth quarter and full year 2014 financial results and highlighted recent corporate progress and near-term miles...



Advertisement
 
Advertisement
 

News Quicklinks